The synthesis of a selective PDE4/TNFα inhibitor

被引:34
|
作者
Caron, S [1 ]
Vazquez, E [1 ]
机构
[1] Pfizer Global Res & Dev, Chem Res & Dev, Groton, CT 06340 USA
关键词
D O I
10.1021/op010223p
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Two syntheses of cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid (1), a selective PDE4/TNF alpha inhibitor are described. The first synthesis relied on a solvolysis of a tertiary benzylic alcohol to the nitrile using TMSCN and on the epimerization of an ester to its thermodynamically favored position prior to its hydrolysis. It was demonstrated that the selectivity was controlled by the rate of hydrolysis of the two diastereomeric esters. The second synthesis proved to be more efficient and used a novel nucleophilic aromatic substitution of a fluoroindazole with the anion of a tertiary nitrile. Another key element of the route was a selective Pinner reaction of a secondary nitrile in the presence of a tertiary nitrile.
引用
收藏
页码:587 / 592
页数:6
相关论文
共 50 条
  • [1] Discovery of Apremilast, a selective PDE4 inhibitor
    Man, Hon-Wah
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [2] Pharmacology of orismilast, a potent and selective PDE4 inhibitor
    Silverberg, Jonathan I.
    French, Lars E.
    Warren, Richard B.
    Strober, Bruce
    Kjoller, Kim
    Sommer, Morten O. A.
    Andres, Philippe
    Felding, Jakob
    Weiss, Anne
    Tutkunkardas, Deniz
    Skak-Nielsen, Tine
    Guttman, Emma
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (04) : 721 - 729
  • [3] Pharmacokinetic characteristics of the selective phosphodiesterase 4 (PDE4)-inhibitor roflumilast
    Bethke, T. D.
    Lahu, G.
    Moll-Schueler, I.
    Gleiter, C. H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (21-22) : A59 - A59
  • [4] Pharmacokinetic characteristics of the selective phosphodiesterase 4 (PDE4)-inhibitor roflumilast
    Bethke, T. D.
    Lahu, G.
    Gooss, A.
    Gleiter, C. H.
    SWISS MEDICAL WEEKLY, 2010, 140 (13-14) : 13S - 14S
  • [5] Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration
    Chapman, Richard W.
    House, Aileen
    Richard, Jennifer
    Prelusky, Dan
    Lamca, James
    Wang, Peng
    Lundell, Dan
    Wu, Ping
    Ting, Pauline C.
    Lee, Joe F.
    Aslanian, Robert
    Phillips, Jonathan E.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 643 (2-3) : 274 - 281
  • [6] Effect of a selective phosphodiesterase 4 (PDE4) inhibitor on hyperoxia toxicity in rat
    Mehats, C.
    Franco, M-L
    Boucherat, O.
    Schmitz, T.
    Bourbon, J. R.
    Delacourt, C.
    Jarreau, P-H
    ACTA PAEDIATRICA, 2007, 96 : 42 - 43
  • [7] A Practical Synthesis of the PDE4 Inhibitor, KW-4490
    Yanagisawa, Arata
    Nishimura, Koichiro
    Ando, Kyoji
    Nezu, Tetsuya
    Maki, Ayako
    Kato, Sachiko
    Tamaki, Wakako
    Imai, Eiichiro
    Mohri, Shin-ichiro
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2010, 14 (05) : 1182 - 1187
  • [8] Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
    Schafer, P. H.
    Parton, A.
    Capone, L.
    Cedzik, D.
    Brady, H.
    Evans, J. F.
    Man, H. -W.
    Muller, G. W.
    Stirling, D. I.
    Chopra, R.
    CELLULAR SIGNALLING, 2014, 26 (09) : 2016 - 2029
  • [9] In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitor
    Cenacchi, Valentina
    Battaglia, Rosangela
    Cinato, Flavio
    Riccardi, Benedetta
    Spinabelli, Daniele
    Brogin, Giandomenico
    Puccini, Paola
    Pezzetta, Daniele
    XENOBIOTICA, 2015, 45 (08) : 693 - 710
  • [10] Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4
    Wegesser, Teresa
    Coppi, Aldo
    Harper Jr, Tod
    Paris, Maria
    Minocherhomji, Sheroy
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2021, 125